James B. Breitmeyer - 03 Jan 2024 Form 4 Insider Report for Oncternal Therapeutics, Inc.

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: N/A
Reported as of: 03 Jan 2024
Net transaction value: -$27,504
SEC form: 4
Accepted by SEC: 05 Jan 2024, 16:00:17 UTC
Prior SEC filing: 04 Oct 2023
Next SEC filing: 15 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/Chase C. Leavitt, Attorney-in-fact

Key filing fact

James B. Breitmeyer filed Form 4 for Oncternal Therapeutics, Inc. on 05 Jan 2024.

Key facts

This page summarizes James B. Breitmeyer's Form 4 filing for Oncternal Therapeutics, Inc..
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 05 Jan 2024, 16:00.

Change

Previous filing in this sequence was filed on 04 Oct 2023.
Current net transaction value: -$27,504.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ONCT transaction

Common Stock

Tax liability

Transaction value: $25,279
Shares: -50,955
Change %: -10%
Price: $0.4961
Shares after: 443,034
Date: 03 Jan 2024
Ownership: Direct
Footnotes: F1

ONCT transaction

Common Stock

Tax liability

Transaction value: $2,225
Shares: -4,485
Change %: -23%
Price: $0.4961
Shares after: 15,426
Date: 03 Jan 2024
Ownership: By Spouse
Footnotes: F1

ONCT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 196,544
Date: 03 Jan 2024
Ownership: By Family Trust

ONCT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 733
Date: 03 Jan 2024
Ownership: By Child

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .